Cargando…

Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical Trials

Recent years have seen tremendous progress towards therapy of many previously incurable neuromuscular diseases. This new context has acted as a driving force for the development of novel non-invasive outcome measures. These can be organized in three main categories: functional tools, fluid biomarker...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlier, Pierre G., Marty, Benjamin, Scheidegger, Olivier, Loureiro de Sousa, Paulo, Baudin, Pierre-Yves, Snezhko, Eduard, Vlodavets, Dmitry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5271435/
https://www.ncbi.nlm.nih.gov/pubmed/27854210
http://dx.doi.org/10.3233/JND-160145
_version_ 1782501352701689856
author Carlier, Pierre G.
Marty, Benjamin
Scheidegger, Olivier
Loureiro de Sousa, Paulo
Baudin, Pierre-Yves
Snezhko, Eduard
Vlodavets, Dmitry
author_facet Carlier, Pierre G.
Marty, Benjamin
Scheidegger, Olivier
Loureiro de Sousa, Paulo
Baudin, Pierre-Yves
Snezhko, Eduard
Vlodavets, Dmitry
author_sort Carlier, Pierre G.
collection PubMed
description Recent years have seen tremendous progress towards therapy of many previously incurable neuromuscular diseases. This new context has acted as a driving force for the development of novel non-invasive outcome measures. These can be organized in three main categories: functional tools, fluid biomarkers and imagery. In the latest category, nuclear magnetic resonance imaging (NMRI) offers a considerable range of possibilities for the characterization of skeletal muscle composition, function and metabolism. Nowadays, three NMR outcome measures are frequently integrated in clinical research protocols. They are: 1/ the muscle cross sectional area or volume, 2/ the percentage of intramuscular fat and 3/ the muscle water T2, which quantity muscle trophicity, chronic fatty degenerative changes and oedema (or more broadly, “disease activity”), respectively. A fourth biomarker, the contractile tissue volume is easily derived from the first two ones. The fat fraction maps most often acquired with Dixon sequences have proven their capability to detect small changes in muscle composition and have repeatedly shown superior sensitivity over standard functional evaluation. This outcome measure will more than likely be the first of the series to be validated as an endpoint by regulatory agencies. The versatility of contrast generated by NMR has opened many additional possibilities for characterization of the skeletal muscle and will result in the proposal of more NMR biomarkers. Ultra-short TE (UTE) sequences, late gadolinium enhancement and NMR elastography are being investigated as candidates to evaluate skeletal muscle interstitial fibrosis. Many options exist to measure muscle perfusion and oxygenation by NMR. Diffusion NMR as well as texture analysis algorithms could generate complementary information on muscle organization at microscopic and mesoscopic scales, respectively. (31)P NMR spectroscopy is the reference technique to assess muscle energetics non-invasively during and after exercise. In dystrophic muscle, (31)P NMR spectrum at rest is profoundly perturbed, and several resonances inform on cell membrane integrity. Considerable efforts are being directed towards acceleration of image acquisitions using a variety of approaches, from the extraction of fat content and water T2 maps from one single acquisition to partial matrices acquisition schemes. Spectacular decreases in examination time are expected in the near future. They will reinforce the attractiveness of NMR outcome measures and will further facilitate their integration in clinical research trials.
format Online
Article
Text
id pubmed-5271435
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-52714352017-01-30 Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical Trials Carlier, Pierre G. Marty, Benjamin Scheidegger, Olivier Loureiro de Sousa, Paulo Baudin, Pierre-Yves Snezhko, Eduard Vlodavets, Dmitry J Neuromuscul Dis Review Recent years have seen tremendous progress towards therapy of many previously incurable neuromuscular diseases. This new context has acted as a driving force for the development of novel non-invasive outcome measures. These can be organized in three main categories: functional tools, fluid biomarkers and imagery. In the latest category, nuclear magnetic resonance imaging (NMRI) offers a considerable range of possibilities for the characterization of skeletal muscle composition, function and metabolism. Nowadays, three NMR outcome measures are frequently integrated in clinical research protocols. They are: 1/ the muscle cross sectional area or volume, 2/ the percentage of intramuscular fat and 3/ the muscle water T2, which quantity muscle trophicity, chronic fatty degenerative changes and oedema (or more broadly, “disease activity”), respectively. A fourth biomarker, the contractile tissue volume is easily derived from the first two ones. The fat fraction maps most often acquired with Dixon sequences have proven their capability to detect small changes in muscle composition and have repeatedly shown superior sensitivity over standard functional evaluation. This outcome measure will more than likely be the first of the series to be validated as an endpoint by regulatory agencies. The versatility of contrast generated by NMR has opened many additional possibilities for characterization of the skeletal muscle and will result in the proposal of more NMR biomarkers. Ultra-short TE (UTE) sequences, late gadolinium enhancement and NMR elastography are being investigated as candidates to evaluate skeletal muscle interstitial fibrosis. Many options exist to measure muscle perfusion and oxygenation by NMR. Diffusion NMR as well as texture analysis algorithms could generate complementary information on muscle organization at microscopic and mesoscopic scales, respectively. (31)P NMR spectroscopy is the reference technique to assess muscle energetics non-invasively during and after exercise. In dystrophic muscle, (31)P NMR spectrum at rest is profoundly perturbed, and several resonances inform on cell membrane integrity. Considerable efforts are being directed towards acceleration of image acquisitions using a variety of approaches, from the extraction of fat content and water T2 maps from one single acquisition to partial matrices acquisition schemes. Spectacular decreases in examination time are expected in the near future. They will reinforce the attractiveness of NMR outcome measures and will further facilitate their integration in clinical research trials. IOS Press 2016-03-03 /pmc/articles/PMC5271435/ /pubmed/27854210 http://dx.doi.org/10.3233/JND-160145 Text en IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Carlier, Pierre G.
Marty, Benjamin
Scheidegger, Olivier
Loureiro de Sousa, Paulo
Baudin, Pierre-Yves
Snezhko, Eduard
Vlodavets, Dmitry
Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical Trials
title Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical Trials
title_full Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical Trials
title_fullStr Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical Trials
title_full_unstemmed Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical Trials
title_short Skeletal Muscle Quantitative Nuclear Magnetic Resonance Imaging and Spectroscopy as an Outcome Measure for Clinical Trials
title_sort skeletal muscle quantitative nuclear magnetic resonance imaging and spectroscopy as an outcome measure for clinical trials
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5271435/
https://www.ncbi.nlm.nih.gov/pubmed/27854210
http://dx.doi.org/10.3233/JND-160145
work_keys_str_mv AT carlierpierreg skeletalmusclequantitativenuclearmagneticresonanceimagingandspectroscopyasanoutcomemeasureforclinicaltrials
AT martybenjamin skeletalmusclequantitativenuclearmagneticresonanceimagingandspectroscopyasanoutcomemeasureforclinicaltrials
AT scheideggerolivier skeletalmusclequantitativenuclearmagneticresonanceimagingandspectroscopyasanoutcomemeasureforclinicaltrials
AT loureirodesousapaulo skeletalmusclequantitativenuclearmagneticresonanceimagingandspectroscopyasanoutcomemeasureforclinicaltrials
AT baudinpierreyves skeletalmusclequantitativenuclearmagneticresonanceimagingandspectroscopyasanoutcomemeasureforclinicaltrials
AT snezhkoeduard skeletalmusclequantitativenuclearmagneticresonanceimagingandspectroscopyasanoutcomemeasureforclinicaltrials
AT vlodavetsdmitry skeletalmusclequantitativenuclearmagneticresonanceimagingandspectroscopyasanoutcomemeasureforclinicaltrials